A Genomic Urine Assay for Surveillance of Patients with Bladder Cancer Treated with Radiotherapy
Florus C. de Jong(Erasmus MC Cancer Institute), Joost L. Boormans(Erasmus MC), Tahlita C.M. Zuiverloon(Erasmus MC), Denise Kooper(Erasmus MC), Ellen C. Zwarthoff(Erasmus MC), Joep J. de Jong(Erasmus MC Cancer Institute), Martine Franckena(Erasmus MC), Luca Incrocci(Erasmus MC), Iris G. Iflé(Erasmus MC), Angelique C. van der Made(Erasmus MC Cancer Institute), Wim Van Criekinge(Ghent University Hospital)
Cited by 5
Related Papers
Impact of Molecular Subtypes in Muscle-invasive Bladder Cancer on Predicting Response and Survival after Neoadjuvant Chemotherapy
|European Urology|2017|793
Comprehensive Transcriptional Analysis of Early-Stage Urothelial Carcinoma
|Cancer Cell|2016|654
Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study
|The Lancet Oncology|2021|532
Efficient rescue of integrated shuttle vectors from transgenic mice: a model for studying mutations in vivo.
|Proceedings of the National Academy of Sciences|1989|493
An integrated multi-omics analysis identifies prognostic molecular subtypes of non-muscle-invasive bladder cancer
|Nature Communications|2021|381